Drugs / ABBV-0805
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04127695 | Mar → Jun 2020 | Parkinson disease | AbbVie | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-11-08 | BioArctic AB | Results New data published on ABBV-0805 in Neurobiology of Disease bioarctic.com ↗
The publication includes data showing ABBV-0805’s ability to selectively target soluble toxic α-synuclein aggregates. |
| 2021-09-10 | BioArctic AB | Results New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease bioarctic.com ↗
The presentation, which has been selected as a Top Abstract, includes data showing ABBV-0805’s ability to selectively target soluble toxic α-synuclein aggregates. |
| 2019-02-11 | BioArctic AB | Regulatory BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Application for ABBV-0805 bioarctic.com ↗
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-06 | BioArctic AB | BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease bioarctic.com ↗ |
| 2021-11-08 | BioArctic AB | New data published on ABBV-0805 in Neurobiology of Disease bioarctic.com ↗ |
| 2021-09-10 | BioArctic AB | New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease bioarctic.com ↗ |
| 2019-02-11 | BioArctic AB | BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Application for ABBV-0805 bioarctic.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-0805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04127695 ↗ |
| Route | Intravenous | “ABBV-0805 administered by IV infusion.” NCT04127695 ↗ |